Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the appointment of Christoph Korpus, PhD, MBA, as Chief Business Officer (CBO). Mr. Korpus brings more than 15 years of pharmaceutical experience to Byondis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250324077182/en/
Christoph Korpus, PhD, MBA, Chief Business Officer, Byondis
“Christoph will play a pivotal role in advancing our pipeline of novel antibody conjugates and monoclonal antibody-based therapeutics through clinical development and lead Byondis' business development efforts,” said Byondis’ Founder and CEO Jacques Lemmens, PhD. “With his strong strategic leadership, deep experience in successful partnering and alliance building, along with his background in Oncology drug development, Christoph will be a valuable addition to our leadership team.”
"I am energized to bring my experience to Byondis and to join such an innovative company that is on a mission to make hope real for patients. I believe Byondis, with its fully-integrated research, development and manufacturing capabilities, is uniquely positioned to bring a new generation of ADCs and antibody-based therapies to patients with cancer. I look forward to contributing to the Company’s progress and growth,” said Christoph Korpus, CBO, Byondis.
Prior to joining Byondis, Mr. Korpus was the Director of Global Business Development and Licensing Oncology, at Merck KGaA, Darmstadt, Germany, where he crafted partnering strategies and led negotiations teams for multiple oncology transactions. In previous roles at the Company, he drove cross-company innovation by managing global commercial- and development alliances. Mr. Korpus began his career as a Pharmacist upon graduating with a degree in Pharmacy from Goethe-University in Frankfurt am Main, Germany, and completing his PhD at Ludwig-Maximilians-Universität Munich and the University of Connecticut. He also holds an MBA from Kellogg School of Management at Northwestern University and WHU-Otto Beisheim School of Management.
About Byondis
Driven to improve patients’ lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
Byondis’ broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis’ expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis’ expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house.
The company has a dedicated team of more than 300 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. For more information visit www.byondis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324077182/en/
Contacts
Media contacts
Lisa Buffington
Buffington Comms
E-mail: Communications@Byondis.com
Direct: +31243727741
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hoffmann Green Strengthens Its Intellectual Property With European Patent for H-EVA Cement25.3.2025 19:00:00 EET | Press release
Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative clinker-free cements, today announces the granting of a European patent for its H-EVA 0% clinker cement. This strategic achievement is in line with Hoffmann Green's dynamic international expansion and marks a new stage in the protection of its intellectual property. After more than 6 years of instruction, the H-EVA patent, validated by the European Patent Office under number EP 18 812 243.6, illustrates the added value of the company's Research & Development model, reinforcing its advanced positioning in the decarbonized cement market. Main characteristics of the H-EVA breakthrough technology: Alkali-ettringitic cement; Cement without clinker (0%); Cement in the form of a powder that can be stored in a silo, just like traditional cement; Perfect compatibility
HyperLight Launches 110GHz Intensity Modulator with Record low Vπ, Leveraging Its TFLN Chiplet ™ Platform25.3.2025 18:00:00 EET | Press release
HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard optical fiber and microwave connectors. This industry-first device significantly advances electro-optic modulation capabilities for critical applications, including 400 Gbps-per-lane testing, 100 GHz+ photodiode calibration, high-frequency radio-over-fiber systems, and various other cutting-edge technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325461709/en/ HyperLight's New 110 GHz Low Vπ Intensity Modulator with Record Low 1.4V Half-Wave Voltage Leveraging HyperLight's proprietary TFLN Chiplet™ platform, this revolutionary modulator achieves an unprecedented half-wave voltage (Vπ) of just 1.4 V with bandwidth performance exceeding 110 GHz—setting a new benchmark in high-bandwidth modulation. Combining ultra-low Vπ with minimal insertion loss and ex
Neural Potential: Mouser Series Explores Brain Computer Interfaces at the Intersection of Technology and the Mind25.3.2025 17:18:00 EET | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today announced the release of the latest installment of the Empowering Innovation Together(EIT) technology series, which examines the rapidly evolving field of brain-computer interfaces (BCIs). This series takes a deep dive into the engineering challenges and opportunities in the development of mind-controlled systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325376038/en/ BCIs create direct communication between the brain and external devices, enabling applications like motor function restoration for individuals with paralysis, speech enhancement for those with communication impairments, and even cognitive augmentation. These systems rely on electrode-based neural signal acquisition and advanced signal processing algorithms to translate brain activity into actionable commands. In th
New Milestone as Sweden Enshrines Policy That Can Turn World Smoke-Free25.3.2025 16:57:00 EET | Press release
Sweden has enshrined tobacco harm reduction in public health policy after becoming the first nation to prove it’s the most effective path to a smoke-free future. Thanks to Sweden’s stance on safer nicotine alternatives, just 4.5% of Swedish-born adults now smoke - below the 5% smoke-free threshold. This success has led Parliament to formally adopt harm reduction, reinforcing Sweden’s role as a global leader in public health innovation. Dr. Delon Human, leader of Smoke Free Sweden, says: “Swedes have participated in a long-running harm reduction experiment, providing undeniable proof that replacing smoking with smokeless nicotine dramatically reduces smoking-related disease, disability and premature deaths - a net gain for public health, while reducing expenditure. “With harm reduction now policy in Sweden, every public health decision will reflect this approach. Other countries should adopt Sweden’s model without further delay.” Rather than reducing tobacco use, Sweden now prioritises
Neos Kicks Off Global Indie Game Publishing Business25.3.2025 16:00:00 EET | Press release
Neos has launched "IndieTech Games," a label dedicated to publishing high-quality indie games worldwide, including in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320035646/en/ IndieTechGames Neos entered the game development and publishing business for Nintendo Switch in 2019, starting with the release of "Shin chan: Me and the Professor on Summer Vacation - The Endless Seven-Day Journey" in Japan in 2021. The title later expanded to Asia, Europe, and North America in the following year, and eventually to the rest of the world, achieving cumulative shipments of over 500,000 units. The latest title, "Shin chan: Shiro and the Coal Town," has also been released globally and has been well received, following the success of its predecessor with cumulative shipments exceeding 300,000 units. Through the sales and marketing of our in-house developed titles, we have had more opportunities to engage with games from around
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom